Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Dr Ahmad Ameri


Contact details

Department of Radiation Oncology
Imam Hossein Hospital
Shaheed Madani Street
+98 (0)21 77557999

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title


Gorgani 1

Study hypothesis

Chemoradiation with weekly cisplatin and gemcitabine prolong disease free survival in cervical cancer compared with chemoradiation with weekly cisplatin.

Please note that as of 05/12/2008 this record was updated to reflect that this trial was stopped in January 2008.

Ethics approval

Ethics approval received from the Shaheed Beheshti University of Medical Science (SBMU) Ethics Committee (ref: 691).

Study design

Phase II, randomised clinical trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet


Cervical cancer (FIGO stage IB, II , III, IVA)


Initial workup:
1. Complete physical examination
2. Pelvic examination without anaesthesia by at least two gynaecologists/oncologists
3. Chest X ray
4. Abdomino-pelvic spiral multi-detector Computed Tomograpy (CT) scan with Intravenous (IV) contrast
5. Sigmoidoscopy and colonoscopy if required
6. Complete blood cell counts with platelets, blood urea, serum creatinine, liver enzymes, and urine analysis

1. Radiation therapy:
1.1. Whole pelvic External Beam Radiation Therapy (EBRT) 4500 - 5040 cGy in 25 - 28 fractions with cobalt 60 teletherapy 5 fractions a week. Duration of treatment: 5 to 5.5 weeks.
1.2. Intracavitary brachytherapy (ICRT) with Ce137 2500 - 3000 cGy to point A, 1 to 2 weeks after completion of whole pelvic irradiation. ICRT will be carried out 1-2 week after the end of EBRT.

2. Chemotherapy:
All chemotherapy will be administered weekly during EBRT and ICRT. Anti-emetic drug will be used as per department protocol. Transfusion will be allowed for Hb less than 12 g/dl at start of treatment or any time during therapy to correct it to 12 g/dl.
2.1. Arm A: Following hydration with 1000 ml of normal saline (n/s) for 1 hour, cisplatin 40 mg/m^2 in 500 ml n/s plus 50 ml manitol 20% will be infused for 40 minutes, followed by 500 ml of n/s for 30 minutes
2.2. Arm B: Gemcitabine 100 mg/m^2 in 200 ml n/s for 30 minutes will be added to Arm A chemotherapy

If Absolute Neutrophile Count (ANC) is less than 100 x 10^6/L and/or platelet count less than 100 x 10^9/L chemotherapy will be postponed. Dose modification will not be allowed for any of the drugs. Radiotherapy will be postponed if any Grade 3 or 4 hematological toxicity or diarrhoea occur. Treatment will be resumed when toxicity Grade returns to 1.

Duration of the entire course of treatment: Less than 10 weeks

Periodic evaluation:
1. Complete blood cell counts, blood urea, serum creatinine, and liver enzymes will be checked weekly during treatment on the day of chemotherapy, and every month after treatment for 3 month then every 3 month for 1 year and every 6 month thereafter
2. Pelvic examination without anaesthesia, 40 to 45 days after completion of chemoradiation and then at each visit
3. Chest X ray and abdomino-pelvic CT scan with IV contrast, 40 to 45 days after completion of chemoradiation and then if required

Intervention type



Not Specified

Drug names

Gemcitabine, cisplatin

Primary outcome measures

Two year disease free survival (time from completion of chemoradiation to first pathologically documented local recurrence or distant metastasis out of pelvis).

Secondary outcome measures

The following will be assessed at the end of patient accrual:
1. Clinical complete response rate (complete disappearance of tumor radiologically and clinically in the first evaluation after treatment)
2. Toxicity profile according to the World Health Organization (WHO) criteria
3. Overall survival (time from completion of chemoradiation to death)

Overall trial start date


Overall trial end date


Reason abandoned

Objectives no longer viable


Participant inclusion criteria

1. Women with untreated locally advanced cervical cancer International Federation of Gynaecology and Obstetrics (FIGO) stage IB, II, III, IVA
2. Histologically confirmed Squamous Cell Carcinoma (SCC)
3. Aged between 18 - 70 years
4. Performance status less than or equal to 2 in Eastern Cooperative Oncology Group (ECOG) scale
5. No active co-morbid illness (uncontrolled infection, cardiopulmonary disease, uncontrolled diabetes mellitus)
6. Laboratory data at start of chemotherapy:
6.1. Haemoglobin (Hb) 12 g/dl or corrected to 11 g/dl before the start of therapy
6.2. Platelets (Plt) 100 x 10^9/L
6.3. Absolute Neutrophil Count (ANC) more than or equal to 1.5 x 10^9/L
6.4. Creatinine (Cr) less than or equal to 1.5 x Upper Limit of Normal (ULN)
6.5. Billirubin less than or equal to 1.5 ULN
6.6. Aspartate Aminotransferase (AST) less than or equal to 2 x ULN
6.7. Alanine Aminotransferase (ALT) less than or equal to 2 x ULN

Participant type


Age group




Target number of participants

80 (40 in each group)

Participant exclusion criteria

1. Any metastatic disease
2. Previous pelvic irradiation
3. History of other malignancy except non-melanoma skin cancer
4. Disease out of the pelvis and para-aortic lymph nodes

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Department of Radiation Oncology

Sponsor information


Shaheed Beheshti University of Medical Science (SBMU) (Iran)

Sponsor details

c/o Dr Zhila Abediasl
Velenjak Street
+98 (0)21 22413042

Sponsor type




Funder type


Funder name

Shaheed Beheshti University of Medical Science (SBMU) (Iran)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes